Emcure Pharmaceuticals will market Sanofi's oncology portfolio in India as part of efforts by both partners to leverage the benefits of providing a comprehensive and complementary range of products in the segment.
Emcure Pharmaceuticals will market Sanofi's oncology portfolio in India as part of efforts by both partners to leverage the benefits of providing a comprehensive and complementary range of products in the segment.
This is Sanofi's third alliance with Emcure, after a similar deal for Sanofi-Pasteur’s rabies vaccine Verorab and a non-exclusive distribution...
Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
